Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
De Maeyer L, Van Limbergen E, De Nys K, Moerman P, Pochet N, Hendrickx W, Wildiers H, Paridaens R, Smeets A, Christiaens MR, Vergote I, Leunen K, Amant F, Neven P. De Maeyer L, et al. Among authors: moerman p. J Clin Oncol. 2008 Jan 10;26(2):335-6; author reply 336-8. doi: 10.1200/JCO.2007.14.8411. J Clin Oncol. 2008. PMID: 18182677 No abstract available.
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvement.
Neven P, Brouckaert O, Van Belle V, Vanden Bempt I, Hendrickx W, Cho H, Deraedt K, Van Calster B, Van Huffel S, Moerman P, Amant F, Leunen K, Smeets A, Wildiers H, Paridaens R, Vergote I, Christiaens MR. Neven P, et al. Among authors: moerman p. J Clin Oncol. 2008 Apr 1;26(10):1768-9; author reply 1769-71. doi: 10.1200/JCO.2007.15.6141. J Clin Oncol. 2008. PMID: 18519273 No abstract available.
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens MR, Vergote I, Van Huffel S, Neven P. Van Belle V, et al. Among authors: moerman p. J Clin Oncol. 2010 Sep 20;28(27):4129-34. doi: 10.1200/JCO.2009.26.4200. Epub 2010 Aug 16. J Clin Oncol. 2010. PMID: 20713855
Are gene signatures better than traditional clinical factors?
Neven P, Van Belle V, Brouckaert O, Pintens S, Paridaens R, Christiaens MR, Deraedt K, Moerman P. Neven P, et al. Among authors: moerman p. Lancet Oncol. 2008 Mar;9(3):197-8; author reply 198-9. doi: 10.1016/S1470-2045(08)70047-0. Lancet Oncol. 2008. PMID: 18308244 No abstract available.
Triple-negative breast cancer.
Stockmans G, Deraedt K, Wildiers H, Moerman P, Paridaens R. Stockmans G, et al. Among authors: moerman p. Curr Opin Oncol. 2008 Nov;20(6):614-20. doi: 10.1097/CCO.0b013e328312efba. Curr Opin Oncol. 2008. PMID: 18841042 Review.
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers.
Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P. Brouckaert O, et al. Among authors: moerman p. Ann Oncol. 2012 Oct;23(10):2578-2584. doi: 10.1093/annonc/mds062. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492698 Free article.
Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients.
Vandorpe T, Smeets A, Van Calster B, Van Hoorde K, Leunen K, Amant F, Moerman P, Deraedt K, Brouckaert O, Van Huffel S, Wildiers H, Christiaens MR, Neven P. Vandorpe T, et al. Among authors: moerman p. Breast Cancer Res Treat. 2011 Jul;128(2):429-35. doi: 10.1007/s10549-011-1565-4. Epub 2011 May 12. Breast Cancer Res Treat. 2011. PMID: 21562708
347 results